CONGENITAL BLEEDING DISORDER
Clinical trials for CONGENITAL BLEEDING DISORDER explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL BLEEDING DISORDER trials appear
Sign up with your email to follow new studies for CONGENITAL BLEEDING DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly shot could help kids with hemophilia b avoid bleeding
Disease control CompletedThis study tested a new long-acting factor IX drug (nonacog beta pegol) in 25 children with hemophilia B. The drug is given as a weekly injection to prevent bleeding episodes. The main goal was to check safety and whether the body develops antibodies that block the treatment. Res…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for kids with hemophilia b: Long-Acting drug shows promise in preventing bleeds
Disease control CompletedThis study tested a new long-acting clotting factor drug called nonacog beta pegol in 54 young children with hemophilia B who had not been treated before. The drug was given regularly to prevent bleeding episodes and also to treat any bleeds that occurred. The main goal was to se…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for kids with hemophilia: Long-Acting clotting factor shows promise
Disease control CompletedThis trial tested a long-acting clotting factor called N8-GP in 124 young children (under 6 years old) with severe hemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The study found that N8-GP helped control ble…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Real-World use of clotting factor in iraqi haemophilia patients examined
Knowledge-focused CompletedThis completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-wor…
Matched conditions: CONGENITAL BLEEDING DISORDER
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC